Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Positive Expiratory Pressure on the Management of Chest Trauma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04548466
Recruitment Status : Completed
First Posted : September 14, 2020
Last Update Posted : September 14, 2020
Sponsor:
Information provided by (Responsible Party):
Hospital de Granollers

Brief Summary:

Chest trauma (CT) are a common problem in our environment caused mainly by traffic accidents and causal and domestic accidents among the elderly population. CTs, in some situations, can lead to sequelae such as fibrothorax secondary to hemothorax and / or empyema and residual chronic pain. Clinical regulations and guidelines recommend a guideline for chest physiotherapy (CP) for all patients with rib fractures, but there is little scientific evidence. It would be interesting to establish CP treatment protocols and describe the most appropriate techniques according to the type and stages of thoracic trauma consolidation.

Objective: To evaluate the effect of Positive Expiratory Pressure (PEP) breathing added to conventional CP in terms of aid secretion clearance, pain control, pleuropulmonary radiological abnormalities, restoration of lung function, and admission days in the immediate phase of the CT.


Condition or disease Intervention/treatment Phase
Thoracic Fracture Device: PEP bottle Not Applicable

Detailed Description:

After acceptance to participate in the study, patients will be computerized randomized into 2 groups:

  • PEP group: positive expiratory pressure breathing.
  • CONTROL group: conventional CP treatment without positive pressure brething. The period between day 0 and 20 days post-trauma is considered an immediate phase of CT.

Once admitted, an initial evaluation by the doctor will be performed, and pleuro-pulmonary complications, the presence of respiratory failure, and pain control will be evaluated. The chest physiotherapist will perform a clinical and secretion assessment using the Seva test and a dynamic costal examination. The medical treatment of pain control will begin, and the treatment of CP will begin, where it will be randomized in 2 groups: 1- PEP group: positive expiratory pressure breathing with the help of a PEP bottle device. 2-CONTROL group: conventional CP treatment without positive pressure breathing will be daily FR sessions, on weekdays. Upon admission, hospital discharge and post-discharge, radiological checks (simple radiography) will be performed and forced vital capacity will be measured with forced spirometry.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Positive Expiratory Pressure on the Management of Chest Trauma: a Randomized Controlled Trial
Actual Study Start Date : October 2015
Actual Primary Completion Date : September 2016
Actual Study Completion Date : September 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
No Intervention: CONTROL group
Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization.
Experimental: PEP group
Chest physiotherapy depending on the location of the ribs fractures techniques are performed: 1. Postural control techniques; 2. Airways clearance techniques; 3. Breathing exercise (diaphragmatic breathing). 4. Early mobilization. 5. Positive expiratory pressure breathing (PEP bottle)
Device: PEP bottle



Primary Outcome Measures :
  1. Aid secretion clearance [ Time Frame: 1 month ]
    To determine if PEP bottle improves the secretion clearance


Secondary Outcome Measures :
  1. Resolution of pleural lesions [ Time Frame: 1 month ]
    To analysed if PEP bottle allows faster resolution of pleural lesions

  2. Improve lung function [ Time Frame: 1 month ]
    To determine if PEP bottle improves lung function tests

  3. Reduce hospital stay [ Time Frame: 1 month ]
    To assess if PEP bottle decreased hospital stay



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 88 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chest trauma with three or more rib fractures with or without hemopneumothorax
  • Failure to meet any exclusion criteria

Exclusion Criteria:

  • Non-cooperative patients for not understanding chest physiotherapy techniques.
  • Presence of respiratory failure on admission: PaO2 <60mmHg i / or PaCO2> 50mmHg.
  • Medical indication for mechanical ventilation or non-invasive ventilatory support.
  • Presence of undrained pneumothorax.
  • Complications that limit early mobility.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04548466


Locations
Layout table for location information
Spain
Inmaculada Castillo
Seva, Barcelona, Spain, 08553
Sponsors and Collaborators
Hospital de Granollers
Investigators
Layout table for investigator information
Study Chair: Gemma Molist Hospital de Granollers
Publications:
Layout table for additonal information
Responsible Party: Hospital de Granollers
ClinicalTrials.gov Identifier: NCT04548466    
Other Study ID Numbers: CT-positive expiratory
First Posted: September 14, 2020    Key Record Dates
Last Update Posted: September 14, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Thoracic Injuries
Wounds and Injuries